Ignite Creation Date:
2024-06-16 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 3:30 PM
Study NCT ID:
NCT06427941
Status:
RECRUITING
Last Update Posted:
2024-06-26
First Post:
2024-05-20
Brief Title:
A Phase 1 Study of BGB-B2033 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors
Sponsor:
BeiGene
Organization:
BeiGene
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Metastatic Solid Tumor |
| Metastatic Hepatocellular Carcinoma |
| Advanced Hepatocellular Carcinoma |
| Alpha-fetoprotein AFP-Producing Gastric Cancer |
| Extragonadal Yolk Sac Tumors |
| Glypican-3 GPC3-Positive Squamous Non-small Cell Lung Cancer |
Keywords:
| Name | View |
|---|---|
| HCC | View |
| GC | View |
| GPC-3 | View |
| GPC3-positive squamous non-small cell lung cancer | View |
| NSCLC | View |
| BGB-B2033 | View |
| tislelizumab | View |
| metastatic hepatocellular carcinoma | View |
| Advanced Hepatocellular Carcinoma | View |
| alpha-fetoprotein AFP-producing gastric cancer | View |
| extragonadal yolk sac tumors | View |
| Squamous Non-small-cell Lung Cancer | View |
| Non-dysgerminomas squamous non-small cell lung cancer | View |